VMS Rehab Systems Inc
VMS Rehab Systems, Inc. engages in generic drug and home healthcare businesses. It develops and tests generic tadalafil products. The company also sells orthopedic wedge seat cushions for relieving the discomfort and/or pain caused by other lower body medical issues, including pilonidal disease, piles disease, and hemorrhoids to home healthcare retail networks in Canada. VMS Rehab Systems, Inc. w… Read more
VMS Rehab Systems Inc (VRSYF) - Net Assets
Latest net assets as of March 2018: $-377.39K USD
Based on the latest financial reports, VMS Rehab Systems Inc (VRSYF) has net assets worth $-377.39K USD as of March 2018.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.94K) and total liabilities ($387.32K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-377.39K |
| % of Total Assets | -3797.81% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
VMS Rehab Systems Inc - Net Assets Trend (2012–2017)
This chart illustrates how VMS Rehab Systems Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VMS Rehab Systems Inc (2012–2017)
The table below shows the annual net assets of VMS Rehab Systems Inc from 2012 to 2017.
| Year | Net Assets | Change |
|---|---|---|
| 2017-12-31 | $-375.31K | -26.32% |
| 2016-12-31 | $-297.11K | -150786.70% |
| 2013-12-31 | $-196.91 | +25.52% |
| 2012-12-31 | $-264.38 | -- |
Equity Component Analysis
This analysis shows how different components contribute to VMS Rehab Systems Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 60125052.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2017)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $226.21K | % |
| Total Equity | $-375.31K | 100.00% |
VMS Rehab Systems Inc Competitors by Market Cap
The table below lists competitors of VMS Rehab Systems Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NZJ Holdings Inc
PINK:NZIH
|
$0.91 |
|
T.W. Christian Inc
PINK:TWCI
|
$0.91 |
|
Meltronix Inc
PINK:MTNX
|
$0.91 |
|
Rain Forest International Inc
PINK:RFII
|
$0.91 |
|
Radiant Energy Corporation
PINK:RDEGF
|
$0.91 |
|
DNA Brands Inc
PINK:DNAX
|
$0.91 |
|
Silverstar Holdings Ltd
PINK:SSTRF
|
$0.91 |
|
Amazonas Florestal Ltd
PINK:AZFL
|
$0.91 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VMS Rehab Systems Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2016 to 2017, total equity changed from -297,110 to -375,309, a change of -78,199.
- Net loss of 117,016 reduced equity.
- Share repurchases of 59,709 reduced equity.
- Other factors increased equity by 98,526.
Equity Change Factors (2016 to 2017)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-117.02K | -31.18% |
| Share Repurchases | $59.71K | -15.91% |
| Other Changes | $98.53K | +26.25% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares VMS Rehab Systems Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.00 | $0.00 | x |
| 2013-12-31 | $-0.73 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VMS Rehab Systems Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -321.21%
- • Asset Turnover: 3.51x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -14.35% | 2.52x | 0.00x | $17.84 |
| 2013 | 0.00% | 64.77% | 16.11x | 0.00x | $66.13 |
| 2016 | 0.00% | -291.84% | 0.17x | 0.00x | $-83.17K |
| 2017 | 0.00% | -321.21% | 3.51x | 0.00x | $-79.49K |
Industry Comparison
This section compares VMS Rehab Systems Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VMS Rehab Systems Inc (VRSYF) | $-377.39K | 0.00% | N/A | $0.91 |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |